NUVB News and Press, Nuvation Bio Inc. Class A From 11/17/21

David Einhorn's 13F stock portfolio value decreased from $1.59B to $1.49B this quarter. Greenlight increased The ODP Group, LivaNova plc, and Sonos while reducing Concentrix and AerCap Holdings. The largest three positions are at ~44% of the portfolio. As of Q3 2021, the overall p...

Seth Klarman’s 13F portfolio value decreased from $12.33B to $10.88B this quarter. Baupost Group increased Liberty SiriusXM, Theravance Biopharma, and Joby Aviation while decreasing eBay, Willis Towers Watson, International Flavors & Fragrances, and PG&E. The portfo...

Nuvation Bio (NYSE:NUVB): Q3 GAAP EPS of -$0.11. Press Release. For further details see: Nuvation Bio reports Q3 results

Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business Update Enrollment ongoing in phase 1/2 study of NUV-422 for the treatment of multiple difficult-to-treat cancers Strong balance sheet with cash, cash equivalents and marketable securities of $791...

BTIG analyst Kaveri Pohlman assumed coverage of Replimune Group (NASDAQ:REPL) with a Buy rating and $60 price target (PT), implying a premium of ~93% from last close. The analyst assumed coverage of 10 more Immuno-oncology companies, and believes "much of the most promising work" involves bro...

David Abrams’ 13F portfolio value increased marginally this quarter from $4.44B to $4.50B. The number of positions remained steady at 16. Abrams Capital Management increased Change Healthcare during the quarter. The top three positions are Lithia Motors, Facebook, and Asbur...

Seth Klarman’s 13F portfolio value decreased from $12.56B to $12.33B this quarter. Baupost Group increased Micron Technology and Facebook while dropping Fox Corp. The portfolio continues to be heavily concentrated with the top three positions accounting for ~32% of the 13F ...

Nuvation Bio (NYSE:NUVB): Q2 GAAP EPS of -$0.09 Cash, cash equivalents and marketable securities of $806.6M. Press Release For further details see: Nuvation Bio reports Q2 results

Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides Business Update Ongoing enrollment in Phase 1/2 study of lead investigational compound NUV-422 for the treatment of adult patients with malignant gliomas; protocol amendment submitted to expand into addition...

[[ABCB]], [[ASB]], [[BOOM]], [[CE]], [[COF]], [[CSL]], [[EIG]], [[FE]], [[FFBC]], [[FFIN]], [[GBCI]], [[HTH]], [[INTC]], [[NUVB]], [[OZK]], [[RHI]] ,[[RNR]], [[SAM]],[[SIVB]], [[SKX]], [[SNAP]] ,[[TWTR]] ,[[VICR]], [[VRSN]],[[WRB]], [[WSFS]]For Seeking Alpha's full earnings season c...